Pathway link TEM-MTORC1

Temsirolimus ⊣ mTORC1

Temsirolimus inhibits mTORC1.

Temsirolimus is the IV version of rapamycin and, as far as we know, the first mTOR-blocking drug shown to help patients live longer in a controlled trial (in advanced kidney cancer).

Temsirolimus is the intravenous rapamycin analogue, and, to our knowledge, the first mTOR inhibitor to show an overall-survival benefit in a randomised trial.

The conditions it holds under

HUD2007 shows the clinical effect (overall survival in poor-prognosis metastatic kidney cancer). It did not measure mTORC1 activity; that temsirolimus inhibits mTORC1 rests on the FKBP12-dependent mechanism it shares with rapamycin.

Time it takes

hours

Step

indirect (through steps not drawn here)

Measured in

human

Where in the cell

lysosome

Reaches people?

shown in people

How settled

settled in the literature

Studies behind it

Points the other way

No study in the Atlas contradicts this link. That means none in this curated set, not none in the literature.

Who has checked this

Checked by

No researcher outside the project has checked this link yet.

Curator sign-off

Not signed off yet. This link was drafted with AI help and has not been reviewed link by link; treat it as a proposal until it is.

Curated by

Oliver Barton, with AI help for drafting; see how links are checked.

“Inhibits” describes the effect on the target's activity, not on how much of it there is.

“How settled” describes how far researchers in the field agree. It is not the same as the sign-off above, which only says whether a named curator has checked this page.

If this link rests on your own work: a click on “This looks right” below, or a short note through “Report an error”, helps us more than anything else on this page.

← The whole pathway · This link as JSON